SCHEMBL8932043

SCHEMBL8932043

CC(COCCC(=O)O)(COCCC(=O)O)COCCC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
LMNA P02545 5/20 0.36
EGLN1 Q9GZT9 2/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
FFAR3 O14843 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
SLC15A2 Q16348 1/20 0.35
TSHR P16473 4/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
HMGCR P04035 1/20 0.33
CHRM1 P11229 1/20 0.33
TBXA2R P21731 1/20 0.33
ADRA1A P35348 1/20 0.33
NAALAD2 Q9Y3Q0 1/20 0.33
PLA2G4B P0C869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5712795 0.89 L3MBTL1 (0.36) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL439265 0.86 ALDH1A1 (0.37) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL9883735 0.86 ALDH1A1 (0.37) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL16692642 0.84 ALDH1A1 (0.42) ALDH1A1LMNATSHRSLC22A6AKR1B1
SCHEMBL21896383 0.84 HMGCR (0.37) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL1781906 0.82 BLM (0.34) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL12227935 0.82 ALDH1A1 (0.36) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL19646421 0.81 MEN1 (0.38) TSHR
SCHEMBL23935415 0.80 ALDH1A1 (0.33) ALDH1A1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL10911455 0.80 NAALAD2 (0.34) ALDH1A1LMNAEGLN1ALKBH5SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013000970-A1 BIS TRIDENTATE W3O2 CLUSTERS FOR X-RAY IMAGING BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-01-03 WO claimed
EP-2540321-A1 Bis Tridentate W3O2 Clusters for X-Ray imaging Bayer Intellectual Property GmbH (DE) 2013-01-02 EP claimed
US-9714421-B2 Compositions and methods IONIS PHARMACEUTICALS, INC. (US) 2017-07-25 US disclosed
US-20170183661-A1 COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-29 US disclosed
US-20170166899-A1 COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-15 US disclosed
US-20170159055-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-08 US disclosed
US-9671396-B2 Solid substrate comprising array of dendrons and methods for using the same PARK JOON WON (KR) 2017-06-06 US disclosed
US-20170145424-A1 COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS, INC. (US) 2017-05-25 US disclosed
US-9389227-B2 Solid substrate comprising array of dendrons and methods for using the same POSCO (KR) 2016-07-12 US disclosed
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2016-07-07 US disclosed
US-9382540-B2 Compositions and methods for modulating angiopoietin-like 3 expression ISIS PHARMACEUTICALS, INC (US) 2016-07-05 US disclosed
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2012-05-31 US disclosed
US-8106022-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-20080274915-A1 Solid Substrate Comprising Array of Dendrons and Methods for Using the Same PARK JOON WON 2008-11-06 US disclosed
US-20080113353-A1 Cantilevers with fixed end and free end modified by dendron POSTECH FOUNDATION (KR) 2008-05-15 US disclosed
US-20080064070-A1 POLYNUCLEOTIDE SYNTHESIS ON A MODIFIED SURFACE POSTECH FOUNDATION (KR) 2008-03-13 US disclosed
US-20070128623-A1 Cantilevers with fixed end and free end modified by dendron POSTECH FOUNDATION (KR) 2007-06-07 US disclosed
EP-0573848-B1 Bile-acid derivatives, a process for their production and their use as medicines HOECHST AG (DE) 1997-12-03 EP disclosed
US-5428182-A Hypolipidemic agents HOECHST AKTIENGESELLSCHAFT (DE) 1995-06-27 US disclosed
EP-0573848-A2 Bile-acid derivatives, a process for their production and their use as medicines HOECHST AKTIENGESELLSCHAFT (DE) 1993-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145424-A1 COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS SI, FABP2, GNE ALDH1A1 2760/4885LMNA 703/4885EGLN1 1750/4885
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION TEK, PLIN3, FABP3 ALDH1A1 2808/4885LMNA 930/4885EGLN1 79/4885
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC ALDH1A1 4231/4885LMNA 266/4885EGLN1 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.